Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 117.05 2.12% 2.43
ALXN closed up 2.12 percent on Friday, January 18, 2019, on 1.53 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Feb 4

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ALXN trend table...

Date Alert Name Type % Chg
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Crossed Above 50 DMA Bullish 2.12%
Jan 17 MACD Bullish Centerline Cross Bullish 2.12%
Jan 17 Overbought Stochastic Strength 2.12%
Jan 16 50 DMA Resistance Bearish 4.79%
Jan 16 Doji - Bearish? Reversal 4.79%
Jan 16 Overbought Stochastic Strength 4.79%
Jan 15 Pocket Pivot Bullish Swing Setup 4.76%
Jan 15 Multiple of Ten Bullish Other 4.76%

Older signals for ALXN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 140.77
52 Week Low 92.56
Average Volume 1,664,025
200-Day Moving Average 119.5869
50-Day Moving Average 112.736
20-Day Moving Average 104.792
10-Day Moving Average 111.125
Average True Range 4.2892
ADX 20.64
+DI 26.2487
-DI 14.585
Chandelier Exit (Long, 3 ATRs ) 104.5024
Chandelier Exit (Short, 3 ATRs ) 105.4276
Upper Bollinger Band 118.8393
Lower Bollinger Band 90.7447
Percent B (%b) 0.94
BandWidth 26.809871
MACD Line 0.9331
MACD Signal Line -1.0167
MACD Histogram 1.9498
Fundamentals Value
Market Cap 26.13 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 50.67
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 122.80
Resistance 3 (R3) 122.26 119.82 121.84
Resistance 2 (R2) 119.82 118.35 120.08 121.52
Resistance 1 (R1) 118.43 117.45 119.13 118.97 121.20
Pivot Point 115.99 115.99 116.33 116.25 115.99
Support 1 (S1) 114.60 114.52 115.30 115.14 112.90
Support 2 (S2) 112.16 113.62 112.42 112.58
Support 3 (S3) 110.77 112.16 112.26
Support 4 (S4) 111.31